February 13, 2018 / 12:06 PM / in 8 months

BRIEF-Eli Lilly Announces Positive Top-Line Phase 3 Results For Taltz

Feb 13 (Reuters) - Eli Lilly And Co:

* LILLY ANNOUNCES POSITIVE TOP-LINE PHASE 3 RESULTS FOR TALTZ® (IXEKIZUMAB) IN ANKYLOSING SPONDYLITIS (RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS)

* ELI LILLY AND CO - TALTZ(®) (IXEKIZUMAB) MET PRIMARY AND ALL KEY SECONDARY ENDPOINTS IN COAST-V

* ELI LILLY AND CO - PLANS TO SUBMIT DETAILED DATA FROM COAST-V FOR DISCLOSURE AT SCIENTIFIC MEETINGS AND IN PEER-REVIEWED JOURNALS LATER THIS YEAR

* ELI LILLY AND CO - PLANS TO SUBMIT FOR REGULATORY APPROVALS PENDING ADDITIONAL DATA FROM ONGOING TALTZ DEVELOPMENT PROGRAM LATER THIS YEAR

* ELI LILLY AND CO - ‍TALTZ DEMONSTRATED A STATISTICALLY SIGNIFICANT IMPROVEMENT IN SIGNS AND SYMPTOMS OF AS, WHEN COMPARED TO PLACEBO​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below